Dergiler / Journal of critical and intensive care (Online) / 2021 / Cilt: 12 - Sayı: 1

Serial C1 Inhibitor Levels in Patients with Ventilator-Associated Pneumonia: A Prospective Observational Study

Sayfa
8–14
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Serial monitoring of C1-INH levels may aid in prediction of prognosis in the early phase of VAP patients, especially those accompanied by septic shock.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: C1-inhibitor (C1-INH), an acute-phase protein, regulates the activation of the complement cascade and acts as a down-regulator of the inflammatory process.
📊
Temel Bulgular & Veri:In experimental models, it was shown that pneumonia with mechanical ventilation is associated with an increase of complement activation in the lungs.
💡
Sonuç & Katkı:Conclusion: Serial monitoring of C1-INH levels may aid in prediction of prognosis in the early phase of VAP patients, especially those accompanied by septic shock.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:2018 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: C1-inhibitor (C1-INH), an acute-phase protein, regulates the activation of the complement cascade and acts as a down-regulator of the inflammatory process. In experimental models, it was shown that pneumonia with mechanical ventilation is associated with an increase of complement activation in the lungs. The primary aim of this study was to evaluate the serial changes of C1-INH levels in patients with ventilator- associated pneumonia (VAP). Methods: Twelve patients were included in this prospective and observational study conducted between June 2018 and February 2019. Blood samples for C1-INH levels were obtained at the time of VAP diagnosis and on the 2 nd , 4 th , and 6 th days following diagnosis (total of 48 samplings). At the time of C1-INH sampling, patients were screened for clinical pulmonary infection score, arterial blood gas analysis, mechanical ventilation parameters, complete blood count, C-reactive protein, procalcitonin levels, and other routine laboratory tests. Results: No differences were found between surviving (n=7) and non-surviving (n=5) patients in terms of C1- INH levels at any measurement time (days 0, 2, 4 and 6) (p=0.982, p=0.677, p=0.790, p=0.930, respectively). VAP patients with septic shock had higher C1-INH levels than patients without shock, on the days following the diagnosis. C1-INH levels significantly correlated with concurrently measured white blood cell (R 2 = 0.095, p=0.030), lactate (R 2 =0.109, p=0.012), procalcitonin (R 2 =0.120, p=0.009), alanine aminotransferase (R2 =0.179, p=0.002) levels, and PaO2 / FiO2 ratio (R2 =0.091, p=0.022). Conclusion: Serial monitoring of C1-INH levels may aid in prediction of prognosis in the early phase of VAP patients, especially those accompanied by septic shock.

🔖

Bu Makaleye Atıf Yap

TAŞKIN, G., SELÇUK, A., UYSAL, S. (2022). Serial C1 Inhibitor Levels in Patients with Ventilator-Associated Pneumonia: A Prospective Observational Study. Journal of critical and intensive care (Online), Cilt: 12 - Sayı: 1, 8–14. https://ajindex.com/articles/562280

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Kiaei BA, Ghiasi F, Moradi D. Precalcitonin and C-reactive protein as markers in response to antibiotic treatment in ventilator associated pneumonia in intensive care unit-hospitalized patients. Adv Biomed Res 2015
  2. [CrossRef] 2. Wongsurakiat P, Tulatamakit S. Clinical pulmonary infection score and a spot serum procalcitonin level to guide discontinuation of antibiotics in ventilator-associated pneumonia: a study in a single institution with high prevalence of nonfermentative gram-negative bacilli infection. Ther Adv Respir Dis 2018
  3. 1753466618760134. [CrossRef] 3. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator- associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003
  4. 676–82. [CrossRef] 4. Luyt CE, Guérin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005
  5. 48–53. [CrossRef] 5. Cai S, Dole VS, Bergmeier W, et al. A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol 2005
  6. 6462–6. [CrossRef] 6. Beinrohr L, Harmat V, Dobó J, et al. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem 2007
  7. 21100–9. [CrossRef] 7. Igonin AA, Protsenko DN, Galstyan GM, et al. C1-esterase inhibitor infusion increases survival rates for patients with sepsis*. Crit Care Med 2012
  8. 770–7. [CrossRef] 8. Nuijens JH, Abbink JJ, Wachtfogel YT, et al. Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: Evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med 1992
  9. 159–68. [CrossRef] 9. American Thoracic Society
  10. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005
  11. 388–416. [CrossRef] 10. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia:2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016
  12. e61–111. [CrossRef] 11. Singer M, Deutschman CS, Seymour CW, et al.The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016
  13. 801–10. [CrossRef] 12. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensivel